Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.05
ACT's Cash to Debt is ranked lower than
97% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. ACT: 0.05 )
Ranked among companies with meaningful Cash to Debt only.
ACT' s 10-Year Cash to Debt Range
Min: 0.02  Med: 0.61 Max: 43.62
Current: 0.05
0.02
43.62
Equity to Asset 0.51
ACT's Equity to Asset is ranked lower than
67% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. ACT: 0.51 )
Ranked among companies with meaningful Equity to Asset only.
ACT' s 10-Year Equity to Asset Range
Min: 0.25  Med: 0.63 Max: 0.93
Current: 0.51
0.25
0.93
F-Score: 3
Z-Score: 1.14
M-Score: -1.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -12.28
ACT's Operating margin (%) is ranked lower than
81% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. ACT: -12.28 )
Ranked among companies with meaningful Operating margin (%) only.
ACT' s 10-Year Operating margin (%) Range
Min: -21.33  Med: 13.94 Max: 37.1
Current: -12.28
-21.33
37.1
Net-margin (%) -15.29
ACT's Net-margin (%) is ranked lower than
83% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.85 vs. ACT: -15.29 )
Ranked among companies with meaningful Net-margin (%) only.
ACT' s 10-Year Net-margin (%) Range
Min: -22.48  Med: 9.27 Max: 35.15
Current: -15.29
-22.48
35.15
ROE (%) -7.55
ACT's ROE (%) is ranked lower than
76% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.87 vs. ACT: -7.55 )
Ranked among companies with meaningful ROE (%) only.
ACT' s 10-Year ROE (%) Range
Min: -23.54  Med: 7.99 Max: 22.08
Current: -7.55
-23.54
22.08
ROA (%) -3.81
ACT's ROA (%) is ranked lower than
74% of the 697 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. ACT: -3.81 )
Ranked among companies with meaningful ROA (%) only.
ACT' s 10-Year ROA (%) Range
Min: -13.02  Med: 4.60 Max: 19.77
Current: -3.81
-13.02
19.77
ROC (Joel Greenblatt) (%) -53.21
ACT's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.80 vs. ACT: -53.21 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ACT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -37.89  Med: 32.56 Max: 107.33
Current: -53.21
-37.89
107.33
Revenue Growth (3Y)(%) 17.90
ACT's Revenue Growth (3Y)(%) is ranked higher than
78% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. ACT: 17.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ACT' s 10-Year Revenue Growth (3Y)(%) Range
Min: 6.4  Med: 17.60 Max: 40.5
Current: 17.9
6.4
40.5
EBITDA Growth (3Y)(%) -3.70
ACT's EBITDA Growth (3Y)(%) is ranked lower than
64% of the 476 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. ACT: -3.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ACT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -4.4  Med: 7.60 Max: 52.9
Current: -3.7
-4.4
52.9
» ACT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ACT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Allergan PLC

SymbolPriceYieldDescription
AGNPRA1056.431.295 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A-

Guru Investment Theses on Allergan PLC

Vanguard Health Care Fund Comments on Actavis PLC - Mar 27, 2015

Actavis (ACT) is a specialty pharmaceutical company that develops generic and branded products. We owned Actavis prior to its Forest Labs acquisition but increased our position. We are attracted to the uniqueness of the combined company’s business model, which provides exposure to both generic and branded pharmaceuticals globally. The company’s Irish tax rate could also be strategically important in future mergers and acquisitions. Actavis was the fund’s second-largest holding as of the end of the period.



From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report.



Check out Vanguard Health Care Fund latest stock trades

Bernard Horn Comments on Actavis PLC - Oct 30, 2014

On July 1, Actavis (ACT) announced the completion of its acquisition of Forest Laboratories Inc. (a Fund holding), in a cash and equity transaction valued at approximately $28 billion. We maintained a position in Actavis, as its pro-forma financial statements fit the Polaris valuation profile. As one of the largest generic pharmaceutical companies, Actavis is expected to broaden its product platform with the Forest acquisition, increase operating cash flow and realize $1 billion in cost synergies.

From Bernard Horn (Trades, Portfolio)’s Polaris Global Value Fund Q3 2014 Shareholder Letter.

Check out Bernard Horn latest stock trades

Diamond Hill Capital Comments on Actavis PLC - Jul 25, 2014

We eliminated our position in specialty pharmaceutical company Actavis PLC (ACT) as the price to intrinsic value relationship narrowed. We originally received shares when Actavis bought portfolio holding Warner Chilcott.

From Diamond Hill Capital (Trades, Portfolio)'s Small Cap Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Actavis Inc - Jun 26, 2014

Pharmaceutical company Actavis, Inc. PLC (ACT) announced the acquisition of drug manufacturer Forest Laboratories, Inc. during the quarter for a combination of cash and stock. Investors viewed this as a positive for Actavis due to expected synergies and an increase in the branded drug business as a percent of revenues.



From Diamond Hill Capital's Small Cap Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Francis Chou Comments on Actavis Inc. - Sep 05, 2013

Another big winner was Actavis Inc. (ACT), formerly Watson Pharmaceutical. We first purchased Actavis in 2006 at $25. We kept buying the shares in 2007, and on June 30, 2013, it was priced at $126.22. It shows that when you are accurate in your estimation of intrinsic value and buy them at a significant discount, add in good management and respectable growth in intrinsic value, the investment works out really well. This is true even if you bought them when the market indices were trading at an all-time high. "Value traps" generally occur when you are wrong in your estimation of intrinsic value, pay too much and the company's intrinsic value is static and/or decreasing in value.

From Francis Chou's semi-annual report 2013.

Check out Francis Chou latest stock trades

Top Ranked Articles about Allergan PLC

John Paulson's First-Quarter Moves Alter Largest And Most Valuable Stakes
Hedge fund manager John Paulson (Trades, Portfolio), founder and president of Paulson & Co. Inc., the third-largest hedge fund in the world, has been called “one of the most prominent names in high finance” by The New York Times. He rocketed to prominence by making $3.7 billion in 2007 using credit default swaps in a gamble against the U.S. subprime mortgage lending market. Read more...
John Paulson Buys Actavis, AIG, Valeant, Sells Equinix, Alibaba
Hedge fund giant John Paulson (Trades, Portfolio) just reported his first quarter portfolio. He buys Actavis PLC, AIG, Valeant, Computer Sciences, etc during the 3-months ended 2015-03-31, according to the most recent filings of his investment company, Paulson & Co.. As of 2015-03-31, Paulson & Co. owns 57 stocks with a total value of $19 billion. These are the details of the buys and sells.
Read more...
Vanguard Health Care Fund Comments on Actavis PLC
Actavis (ACT) is a specialty pharmaceutical company that develops generic and branded products. We owned Actavis prior to its Forest Labs acquisition but increased our position. We are attracted to the uniqueness of the combined company’s business model, which provides exposure to both generic and branded pharmaceuticals globally. The company’s Irish tax rate could also be strategically important in future mergers and acquisitions. Actavis was the fund’s second-largest holding as of the end of the period. Read more...
Bernard Horn's Most Heavily Weighted Stocks
Bernard Horn (Trades, Portfolio) of Polaris Global Value Fund currently owns 89 stocks, valued at $275 million, with a quarter over quarter turnover of 4%. Read more...
Dodge & Cox's Top New Buys of Q3
The Dodge & Cox fund in companies that it believes the stock market is undervaluing but have strong potential long-term growth. It returned 8% for the first nine months of the year, just shy of the 8.3% return of the S&P 500. Read more...
A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio
Over the duration of the third quarter the Vanguard Health Care Fund added two new stocks to its holdings. The fund now holds on to 89 stocks valued at $39.18 billion. The following companies are Vanguard's top portfolio holdings. Read more...
Bernard Horn's Polaris Global Fund Buys 4 New Stocks
Bernard Horn (Trades, Portfolio) operates the Maine-based, strict value Polaris Global Value Fund (PGVFX). After a prosperous 2013, Horn predicted single-digit returns for stocks in 2014, which has proved accurate through the first three quarters. He still sees plenty of opportunity around the world, however, writing in his third quarter investor letter: Read more...
Bernard Horn Comments on Actavis PLC
On July 1, Actavis (ACT) announced the completion of its acquisition of Forest Laboratories Inc. (a Fund holding), in a cash and equity transaction valued at approximately $28 billion. We maintained a position in Actavis, as its pro-forma financial statements fit the Polaris valuation profile. As one of the largest generic pharmaceutical companies, Actavis is expected to broaden its product platform with the Forest acquisition, increase operating cash flow and realize $1 billion in cost synergies. Read more...
Diamond Hill Capital Comments on Actavis PLC
We eliminated our position in specialty pharmaceutical company Actavis PLC (ACT) as the price to intrinsic value relationship narrowed. We originally received shares when Actavis bought portfolio holding Warner Chilcott. Read more...

Ratios

vs
industry
vs
history
Forward P/E 14.06
ACT's Forward P/E is ranked higher than
81% of the 244 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.58 vs. ACT: 14.06 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.81
ACT's P/B is ranked higher than
75% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. ACT: 1.81 )
Ranked among companies with meaningful P/B only.
ACT' s 10-Year P/B Range
Min: 1.08  Med: 1.75 Max: 5.9
Current: 1.81
1.08
5.9
P/S 5.19
ACT's P/S is ranked lower than
63% of the 661 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. ACT: 5.19 )
Ranked among companies with meaningful P/S only.
ACT' s 10-Year P/S Range
Min: 0.99  Med: 1.83 Max: 5.37
Current: 5.19
0.99
5.37
PFCF 37.99
ACT's PFCF is ranked higher than
56% of the 289 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.65 vs. ACT: 37.99 )
Ranked among companies with meaningful PFCF only.
ACT' s 10-Year PFCF Range
Min: 6.64  Med: 14.11 Max: 46.2
Current: 37.99
6.64
46.2
POCF 32.17
ACT's POCF is ranked lower than
54% of the 399 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.21 vs. ACT: 32.17 )
Ranked among companies with meaningful POCF only.
ACT' s 10-Year POCF Range
Min: 5.97  Med: 11.74 Max: 33.27
Current: 32.17
5.97
33.27
Current Ratio 1.44
ACT's Current Ratio is ranked lower than
73% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. ACT: 1.44 )
Ranked among companies with meaningful Current Ratio only.
ACT' s 10-Year Current Ratio Range
Min: 1.31  Med: 2.95 Max: 9.8
Current: 1.44
1.31
9.8
Quick Ratio 1.03
ACT's Quick Ratio is ranked lower than
74% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. ACT: 1.03 )
Ranked among companies with meaningful Quick Ratio only.
ACT' s 10-Year Quick Ratio Range
Min: 0.78  Med: 2.06 Max: 8.82
Current: 1.03
0.78
8.82
Days Inventory 121.45
ACT's Days Inventory is ranked lower than
54% of the 616 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.37 vs. ACT: 121.45 )
Ranked among companies with meaningful Days Inventory only.
ACT' s 10-Year Days Inventory Range
Min: 107.12  Med: 128.32 Max: 216.83
Current: 121.45
107.12
216.83
Days Sales Outstanding 99.54
ACT's Days Sales Outstanding is ranked lower than
69% of the 589 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.51 vs. ACT: 99.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACT' s 10-Year Days Sales Outstanding Range
Min: 38.55  Med: 58.25 Max: 103.03
Current: 99.54
38.55
103.03

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.28
ACT's Price/Projected FCF is ranked higher than
81% of the 315 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. ACT: 1.28 )
Ranked among companies with meaningful Price/Projected FCF only.
ACT' s 10-Year Price/Projected FCF Range
Min: 0.59  Med: 1.13 Max: 3.29
Current: 1.28
0.59
3.29
Price/Median PS Value 2.81
ACT's Price/Median PS Value is ranked lower than
85% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. ACT: 2.81 )
Ranked among companies with meaningful Price/Median PS Value only.
ACT' s 10-Year Price/Median PS Value Range
Min: 0.67  Med: 1.35 Max: 5.37
Current: 2.81
0.67
5.37
Earnings Yield (Greenblatt) (%) -1.50
ACT's Earnings Yield (Greenblatt) (%) is ranked lower than
74% of the 698 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. ACT: -1.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ACT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.7  Med: 6.50 Max: 11.4
Current: -1.5
0.7
11.4
Forward Rate of Return (Yacktman) (%) 8.71
ACT's Forward Rate of Return (Yacktman) (%) is ranked higher than
54% of the 307 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. ACT: 8.71 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ACT' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -3.7  Med: 7.90 Max: 16.5
Current: 8.71
-3.7
16.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:A60.Germany, AGN N.Mexico,
Actavis PLC, formerly known as Actavis Limited was incorporated in Ireland on May 16, 2013. It is an integrated specialty pharmaceutical company engaged in development, manufacturing, marketing, sale and distribution of generic, branded generic, brand name, biosimilar and over-the-counter pharmaceutical products. It also develops and out-license generic pharmaceutical products in Europe through its Medis third-party business. It operates in three segments, Actavis Pharma, Actavis Specialty Brands and Anda Distribution. The Actavis Pharma segment includes off-patent pharmaceutical products that are therapeutically equivalent to proprietary products. The Actavis Specialty Brands segment includes patent-protected products and certain trademarked off-patent products that the Company sells and markets as brand pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products manufactured by third parties, as well as by the Company to independent pharmacies, pharmacy chains, pharmacy buying groups and physicians' offices. It competes with generic manufacturers of pharmaceutical products. It is subject to extensive, complex and evolving regulation by the federal government, the FDA, and to a lesser extent, by the U.S. Drug Enforcement Administration Occupational Safety and Health Administration and state government agencies, as well as by various regulatory agencies in foreign countries where its products or product candidates are being manufactured and/or marketed. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other federal statutes and regulations govern or influence the testing, manufacturing, packing, labeling, storing, record keeping, safety, approval, advertising, promotion, sale and distribution of its products.
» More Articles for ACT

Headlines

Articles On GuruFocus.com
John Griffin Shows Stake in Trendy Fitbit Inc. Jun 30 2015 
Acquisition in the Health Care Industry Increased Volatility Jun 27 2015 
Julian Robertson Adds 16 New Stakes to Portfolio Jun 23 2015 
Smart Guru John Paulson Bullish on Actavis Jun 18 2015 
Leith Wheeler Investment Funds First Quarter 2015 Review Jun 15 2015 
Activist Hedge Fund Manager Has Strong Focus on Health Care Stocks Jun 11 2015 
My Top 3 Pharma Stock Picks Jun 09 2015 
Leon Cooperman's Top Holdings Look Attractive Jun 09 2015 
10 Reasons Why Growth Stocks Can Be Appropriate for Retired Investors Jun 04 2015 
John Paulson's First-Quarter Moves Alter Largest And Most Valuable Stakes Jun 01 2015 

More From Other Websites
Business Highlights Jul 02 2015
ALLERGAN PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Jul 02 2015
History Tells Jacob Gottlieb His Top 3 Large-Cap Positions Beat The Market Jul 01 2015
Allergan to Host Second Quarter 2015 Earnings Conference Call and Webcast Jun 29 2015
MW advancing Samlyn Capital in June. KATE continues to drag Jun 26 2015
Billionaire Howard Marks’ Amazing Track Record and Top New Picks Jun 25 2015
Eli Lilly wins UK Alimta drug patent case on appeal, shares jump Jun 25 2015
Smart Guru John Paulson Bullish on Actavis Jun 18 2015
ALLERGAN PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD... Jun 17 2015
10 Stocks George Soros Loves in 2015 Jun 16 2015
Actavis Changes Name to Allergan After Deal For Botox Maker Jun 15 2015
ALLERGAN PLC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jun 15 2015
Billionaire John Griffin’s Top Large-Cap Picks Beat Even Warren Buffett’s Picks Jun 14 2015
Edited Transcript of IRWD presentation 10-Jun-15 8:20pm GMT Jun 11 2015
Edited Transcript of ACT presentation 10-Jun-15 4:20pm GMT Jun 11 2015
Doctor on Demand: Medicine at your fingertips Jun 10 2015
Healthcare Investing Maven Hal Mintz Just Opened A Big Position In This Biotech Firm Jun 10 2015
These Three Positions helped drive Tiger Cubs through May Jun 10 2015
Pro sticks with top picks Jun 10 2015
ACTAVIS PLC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to... Jun 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK